Skip to main content
SpringerLink
Log in

Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison

  • Original Article
  • Published:
Cardiovascular Intervention and Therapeutics Aims and scope Submit manuscript

Abstract

We conducted a retrospective examination of the very long-term outcomes of placing sirolimus (SES) and paclitaxel (PES)-eluting stents in patients with ST-elevation myocardial infarction (STEMI). This was a nonrandomized, retrospective, single-center study that included 872 first STEMI patients who underwent successful placement of either SES (n = 547) or PES from November 2004 to April 2012. The primary end point was the incidence of severe cardiac events comprising cardiac death, nonfatal recurrent myocardial infarction, and definite stent thrombosis (ST). The frequency of target lesion revascularization (TLR) was also compared. A propensity score-matched analysis was used to adjust the 29 baseline variables. In the baseline-adjusted cohorts in 231 STEMI patients in each arm, the frequency of the primary end point in the SES group (5.6 %) during the follow-up duration of 2583 ± 806 days was not significantly different from that in the PES group (6.1 %, follow-up: 1866 ± 699 days). The cumulative primary end point-free ratio in the SES group was not significantly different from that in the PES group (p = 0.503). The frequency of TLR in the SES group (7.5 %) was significantly lower than that in the PES group (16.9 %, p = 0.005), with and the significantly higher cumulative TLR-free ratio in the SES group than that in the PES group (p < 0.001). The very long-term clinical outcomes after SES or PES placement for STEMI patients were statistically equivalent. SES showed the better angiographic outcomes for STEMI compared to PES.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Ishikawa T, Mutoh M, Nakano Y, Endo A, Kubota T, Suzuki T, et al. Retrospective comparison of clinical and angiographic outcomes after primary stenting using sirolimus-eluting and bare-metal stents in nonrandomized consecutive 568 patients with first ST-segment elevated myocardial infarctions. J Cardiol. 2011;57:44–52.

    Article  PubMed  Google Scholar 

  2. Yoshikawa D, Isobe S, Umeda H, Kawai T, Shimizu T, Yamashita K, et al. Three-year prognosis of Japanese patients with ST-elevation myocardial infarction treated with sirolimus-eluting stents. Coron Artery Dis. 2009;20:422–7.

    Article  PubMed  Google Scholar 

  3. Ejiri K, Ishihara M, Dai K, Miki T, Inoue I, Kawagoe T, et al. Three-year follow-up of sirolimus-eluting stents vs. bare metal stents for acute myocardial infarction. Circ J. 2012;76:65–70.

    Article  PubMed  Google Scholar 

  4. Nakata K, Ishikawa T, Nakano Y, Yoshimura M, Mutoh M. Midterm outcomes of bare-metal stenting after primary stenting for ST-segment elevated myocardial infarctions in the drug-eluting stent era: a propensity score-matched comparison with sirolimus-eluting stent. Cardiovasc Interv Ther. 2015;30:234–43.

    Article  CAS  PubMed  Google Scholar 

  5. Kim HS, Lee JH, Lee SW, Kim YH, Park JH, Choi SW, et al. Long-term safety and efficacy of sirolimus- vs. paclitaxel-eluting stent implantation for acute ST-elevation myocardial infarction: 3-year follow-up of the PROSIT trial. Int J Cardiol. 2011;3(147):253–7.

    Article  Google Scholar 

  6. Ishikawa T, Mutoh M, Nakano Y, Suzuki T, Nakata K, Murakami A, et al. Post-discharge clinical and angiographic outcomes of patients presenting within 48 h of STEMI treated with paclitaxel- or sirolimus-eluting stents. J Cardiol. 2012;60:174–9.

    Article  PubMed  Google Scholar 

  7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Academic Research Consortium, et al. Clinical endpoints in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.

    Article  PubMed  Google Scholar 

  8. de la Torre-Hernández JM, Alfonso F, Hernández F, Elizaga J, Sanmartin M, Pinar E, ESTROFA Study Group, et al. Drug-eluting stent thrombosis: results from the multicenter Spanish registry Estudio ESpañol sobre TROmbosis de stents FArmacoactivos (ESTROFA). J Am Coll Cardiol. 2008;51:986–90.

    Article  PubMed  Google Scholar 

  9. Kimura T, Morimoto T, Nakagawa Y, Kawai K, Miyazaki S, Muramatsu T, j-Cypher Registry Investigators, et al. Very late stent thrombosis and late target lesion revascularization after sirolimus-eluting stent implantation: 5-year outcome of the j-Cypher Registry. Circulation. 2012;125:584–91.

    Article  CAS  PubMed  Google Scholar 

  10. Ishikawa T, Nakano Y, Endoh A, Kubota T, Suzuki T, Nakata K, et al. Significantly lower incidence of early definite stent thrombosis of drug-eluting stents after unrestricted use in Japan using ticlopidine compared to western countries using clopidogrel: a retrospective comparison with western mega-studies. J Cardiol. 2009;54:238–44.

    Article  PubMed  Google Scholar 

  11. Simsek C, Magro M, Boersma E, Onuma Y, Nauta S, Daemen J, et al. Comparison of 6-year clinical outcome of sirolimus- and paclitaxel-eluting stents to bare-metal stents in patients with ST-segment elevation myocardial infarction: an analysis of the Rapamycin-eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) and T-SEARCH (Taxus Stent Evaluated at Rotterdam Cardiology Hospital) registries. J Invasive Cardiol. 2011;23:336–41.

    PubMed  Google Scholar 

  12. Ishikawa K, Ueshima H, Ogawa H, Kanamasa K, Saito M, Sasaki J et al (2006) Guidelines for secondary prevention of myocardial infarction (JCS 2006). http://www.j-circ.or.jp/guideline/pdf/JCS2006_ishikawa_h.pdf (in Japanese).

  13. Imai M, Kadota K, Goto T, Fujii S, Yamamoto H, Fuku Y, et al. Incidence, risk factors, and clinical sequelae of angiographic peri-stent contrast staining after sirolimus-eluting stent implantation. Circulation. 2011;123(21):2382–91.

    Article  CAS  PubMed  Google Scholar 

  14. Musto C, Fiorilli R, De Felice F, Patti G, Nazzaro MS, Scappaticci M, et al. Long-term outcome of sirolimus-eluting vs bare-metal stent in the setting of acute myocardial infarction: 5-year results of the SESAMI trial. Int J Cardiol. 2013;166:399–403.

    Article  PubMed  Google Scholar 

  15. Spaulding C, Teiger E, Commeau P, Varenne O, Bramucci E, Slama M, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv. 2011;4:14–23.

    Article  PubMed  Google Scholar 

  16. Kimura T, Morimoto T, Kozuma K, Honda Y, Kume T, Aizawa T, Mitsudo K, Miyazaki S, Yamaguchi T, Hiyoshi E, Nishimura E, Isshiki T, RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122(1):52–61.

    Article  PubMed  Google Scholar 

  17. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol. 2006;48:193–202.

    Article  PubMed  Google Scholar 

  18. Takano M, Yamamoto M, Murakami D, Inami S, Okamatsu K, Seimiya K, et al. Lack of association between large angiographic late loss and low risk of in-stent thrombus: angioscopic comparison between paclitaxel- and sirolimus-eluting stents. Circ Cardiovasc Interv. 2008;1:20–7.

    Article  PubMed  Google Scholar 

  19. Hofma SH, Smits PC, Brouwer J, Velders MA, van’t Hof AW, Queré M, de Vries CJ, van Boven AJ. Long-term follow-up of second-generation everolimus-eluting stents versus first-generation sirolimus-eluting stents in acute myocardial infarction: 3-year results of the XAMI trial. EuroIntervention. 2015;10(11):1280–3.

    Article  PubMed  Google Scholar 

  20. Nakano Y, Ishikawa T, Hino S, Mutoh M. Propensity score matched lesion-based comparison of long-term clinical and angiographic outcomes after placement of sirolimus (Cypher Bx Velocity) and paclitaxel (TAXUS Express)-eluting stents for de novo native coronary stenosis. Cardiovasc Interv Ther. 2014;29(2):93–101.

    Article  CAS  PubMed  Google Scholar 

  21. Nakano Y, Ishikawa T, Mutoh M. Long-term angiographic outcomes of sirolimus- and paclitaxel-eluting stent placement in diabetes, long lesions, and small vessels. Cardiovasc Interv Ther. 2015;30(4):327–37.

    Article  CAS  PubMed  Google Scholar 

  22. Tsutsumi J, Ishikawa T, Nakano Y, Yoshimura M, Mutoh M. Long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement following rotablation for severely calcified lesions: a retrospective nonrandomized study. Cardiovasc Interv Ther. 2015;30(1):29–37.

    Article  CAS  PubMed  Google Scholar 

  23. Ishikawa T, Nakano Y, Mutoh M. Retrospective comparison of midterm clinical and angiographic outcomes after the implantation of paclitaxel- and sirolimus-eluting stents for de novo coronary complex lesions in nonrandomized Japanese patients. Intern Med. 2012;51(19):2695–701.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by a Research Fund from Saitama Cardiovascular and Respiratory Center under Grants 13EC, 14EF, and 15 EB to T.I. MD, PhD.

Author information

Authors and Affiliations

  1. Division of Cardiology, Saitama Cardiovascular Respiratory Center, 1696 Itai, Kumagaya, Saitama, 360-0197, Japan

    Takashi Miyamoto, Tetsuya Ishikawa, Yosuke Nakano & Makoto Mutoh

Authors
  1. Takashi Miyamoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tetsuya Ishikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yosuke Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Makoto Mutoh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Tetsuya Ishikawa.

Ethics declarations

Conflict of interest

None.

Funding source

Saitama Cardiovascular Respiratory Center, Kumagaya, Japan.

Human rights statement

This study was approved by the ethics committee of Saitama Cardiovascular Respiratory Center, and all patients provided written informed consent.

Informed consent

Informed consent were done individually.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Miyamoto, T., Ishikawa, T., Nakano, Y. et al. Very long-term clinical and angiographic outcomes after sirolimus- and paclitaxel-eluting stent placement for ST-elevation myocardial infarction: a propensity score-matched comparison. Cardiovasc Interv and Ther 32, 24–35 (2017). https://doi.org/10.1007/s12928-016-0390-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12928-016-0390-4

Keywords

Search

Navigation